TY - JOUR T1 - Imaging calreticulin for early detection of immunogenic cell death during anticancer treatment JF - Journal of Nuclear Medicine JO - J Nucl Med DO - 10.2967/jnumed.120.245290 SP - jnumed.120.245290 AU - Dong-Yeon Kim AU - Ayoung Pyo AU - Misun Yun AU - Ramar Thangam AU - Sung-Hwan You AU - Ying Zhang AU - Ye-rim Jung AU - Dinh-Huy Nguyen AU - Akhil Venu AU - Hyeon Sik Kim AU - Mee Sun Yoon AU - Yeongjin Hong AU - Jung-Joon Min Y1 - 2021/01/01 UR - http://jnm.snmjournals.org/content/early/2021/01/22/jnumed.120.245290.abstract N2 - Surface-exposed calreticulin (ecto-CRT) is a well-known ‘eat-me’ signal exhibited by dying cells that contributes to their recognition and destruction by the immune system. We assessed the use of a CRT-specific binding peptide for imaging ecto-CRT during immunogenic cell death and its utility for the early prediction of treatment response. Methods: A synthetic CRT-specific peptide KLGFFKR (CRTpep) was labeled with fluorescein isothiocyanate or 18F and characteristics of ecto-CRT was evaluated in colon cancer cell line in vitro and in vivo. Results: In vitro flow cytometry, immunofluorescence staining, and in vivo micro positron emission tomography imaging results showed that CRTpep detected pre-apoptotic cells treated with immunogenic drugs or radiation, but not those treated with the non-immunogenic drug or a non-therapeutic dose of immunogenic drug. Conclusion: The present results indicate that the CRT-specific peptide would enable the prediction of therapeutic response, thereby facilitating early decisions regarding the continuation or discontinuation of immunogenic treatment. ER -